title: [Cardioprotective capabilities of drug meldonium in secondary prevention after percutaneous coronary intervention in patients with documented myocardial ischemia].
abstract: The purpose of research — analysis of capabilities in cytoprotective drug mеldonium, in complex in the cardioprotective effect of secondary prevention after percutaneous coronary intervention (PCI). Patients with stable coronary heart disease (n=35 ) aged ≤65 years with incomplete revascularization at 6 months after PCI and positive exercise test (SFI) were randomized 1:1 to groups controlled physical training (CPT) with intensity 80% and a duration of 2 weeks (10 SFI): group 1 (n=17; 53,9±6,2 years) and group 2 (n=18; 56,1±4,8 years). Patients in Group 1, in addition to SFI mеldonium administered at a dose of 1000 mg/ml intravenously. In the 1st group on the background mеldonium adjunctive therapy showed a significant increase in the duration from 15±2 to 32±7 min for the 10th CPT (p<0.05). Index of maximum oxygen consumption after 10 intense CPT increased to 20.8±1.06 ml/kg/min compared to baseline (18.6±1.1 ml/kg/min, p<0.05) and the control group (18.5±1.5 ml/kg/min, p<0.05). Use of meldonium was also associated with decrease of maximum ST-segment depression (from -0.18±0.1 to 0.10±0.2 mV), increases of exercise duration (from 364±22 to 556±29 s) threshold heart rate (from 118±12 to 132±5 bpm), decrease of time of ST segment recovery to baseline (from 385±32 to 242±22 s, p<0.05). Final level of free fatty acids in the meldonium group was significantly lower than that in the control group (0.248±0.047 vs. 0.265±0.031 mg/dl). Inclusion of meldonium in complex treatment after PCI potentiates cardioprotective effect of intensive CPT as evidenced by the positive dynamics of ECG and biochemical markers of myocardial ischemia.
authors.forename: N P
authors.initials: NP
authors.lastname: Liamina
authors.forename: E V
authors.initials: EV
authors.lastname: Kotel'nikova
authors.forename: É S
authors.initials: ÉS
authors.lastname: Karpova
authors.forename: E A
authors.initials: EA
authors.lastname: Biziaeva
authors.forename: V N
authors.initials: VN
authors.lastname: Senchikhin
authors.forename: T P
authors.initials: TP
authors.lastname: Lipchanskaia
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects*; D061605:Administration, Intravenous; D002316:Cardiotonic Agents / Q000008:administration & dosage; D017023:Coronary Angiography / Q000379:methods; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005080:Exercise Test; D005081:Exercise Therapy / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000008:administration & dosage*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D002316:Cardiotonic Agents; D008763:Methylhydrazines; C050147:3-(2,2,2-trimethylhydrazine)propionate